Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
IONS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.33 - $54.44
Previous Close$34.01
Volume1.91M
Average Volume (3M)1.68M
Market Cap
$5.37B
Enterprise Value$3.10B
Total Cash (Recent Filing)$2.48B
Total Debt (Recent Filing)$212.84M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Feb 19, 2025EPS Estimate
-$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding157,897,287
10 Day Avg. Volume1,387,413
30 Day Avg. Volume1,682,032
Standard Deviation0.09
R-Squared0.05
Alpha-0.00659
Financial Highlights & Ratios
Price to Book (P/B)8.43
Price to Sales (P/S)6.64
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.86
Enterprise Value/Gross Profit3.98
Enterprise Value/Ebitda-11.45
Forecast
1Y Price Target
$61.93Price Target Upside74.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Ionis Pharmaceuticals News
PremiumCompany Announcements
Ionis Pharmaceuticals Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceThe company has a net debt to total capital ratio of 0%, indicating a strong financial position.
Product Launch And Market GrowthStrong launch trajectory for Wainua is expected to continue, driven by its competitive efficacy, at-home self-administration, and capacity to expand the current TTR-PN market.
Regulatory AchievementsWAINZUA recently received a positive CHMP opinion in Europe, and the EMA review remains ongoing.
Bears Say
Drug Efficacy ConcernsUncertainty remains on whether TTR-silencers are better than existing TTR-stabilizers like tafamidis.
Financial PerformanceSpinraza revenue was below consensus as OUS sales decreased due to an annual order from a single country that did not recur in 2024.
Revenue ImpactThe launch of eplontersen ATTR-CM has been delayed to 2027, which impacts potential revenue timelines.
---
Ownership Overview
0.74% Insiders
36.69% Mutual Funds
38.42% Other Institutional Investors
9.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $33.33 and its highest was $54.44 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Feb 19, 2025 which is in 85 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.126 by $0.176.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$1.1.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 157,897,300 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.126. Following the earnings report the stock price went up 0.619%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 138M.
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.93 (74.65% Upside)
$61.93 (74.65% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 531.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.40%
12-Months-Change
Fundamentals
Return on Equity
-73.33%
Trailing 12-Months
Asset Growth
5.01%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
IONS Company Deck
---
IONS Earnings Call
Q3 2024
0:00 / 0:00
---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$61.93
▲(74.65% Upside)
Technical Analysis
AnaptysBio
―
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Best Analysts Covering IONS
1 Year
1 Year Success Rate
17/27 ratings generated profit
1 Year Average Return
+6.17%
reiterated a buy rating 4 months ago
Copying David Lebowitz's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +6.17% per trade.
---